The Canadian company’s initial focus is on Alzheimer’s, spinal cord injury and multiple sclerosis. NervGen’s lead drug candidate, NVG-291, has potential to treat nervous system damage, whether as a result of injury or disease. It is a first-in-class therapeutic administered by injection under the skin.

NVG-291 is currently in a Phase I trial in healthy volunteers to evaluate safety, tolerability and metabolism.